21 CFR Part 211 · Current Good Manufacturing Practice for Finished Pharmaceuticals

§ 211.125 Labeling issuance

Subpart G - Packaging and Labeling Control Official text on eCFR Amendment history

(a) Strict control shall be exercised over labeling issued for use in drug product labeling operations.

(b) Labeling materials issued for a batch shall be carefully examined for identity and conformity to the labeling specified in the master or batch production records.

(c) Procedures shall be used to reconcile the quantities of labeling issued, used, and returned, and shall require evaluation of discrepancies found between the quantity of drug product finished and the quantity of labeling issued when such discrepancies are outside narrow preset limits based on historical operating data. Such discrepancies shall be investigated in accordance with § 211.192 . Labeling reconciliation is waived for cut or roll labeling if a 100-percent examination for correct labeling is performed in accordance with § 211.122(g)(2) .

(d) All excess labeling bearing lot or control numbers shall be destroyed.

(e) Returned labeling shall be maintained and stored in a manner to prevent mixups and provide proper identification.

(f) Procedures shall be written describing in sufficient detail the control procedures employed for the issuance of labeling; such written procedures shall be followed.

Independent copy, not an official legal edition. 21 CFR is a U.S. Government work in the public domain; this text comes from the eCFR and the annual CFR edition, and may lag recent amendments. The authoritative version is on ecfr.gov. Compliome is not affiliated with or endorsed by FDA. Not legal advice.

What FDA inspectors cite under § 211.125

Form FDA 483 observations citing this section, fiscal years 2009–2026 (Drugs).

  • Strict control not exercised over labeling issued 282
  • Procedures Written and Followed 130
  • Label reconciliation discrepancies evaluation/investigation 24
  • Examination of issued labels 19
  • Destruction of excess labels with lot numbers 12
  • Return of labeling 2

Warning letters citing § 211.125

6 FDA warning letters since 2017 cite this section :

FDA guidance that cites § 211.125

Amendment history

Federal Register documents that created or amended this section.